{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=15", "query": { "intervention": "BCAA", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 15652, "total_pages": 1566, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T08:53:09.310Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04761198", "title": "A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "Etigilimab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mereo BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2021-03-23", "completion_date": "2023-10-30", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Greenbrae, California • Los Angeles, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761198" }, { "nct_id": "NCT00768287", "title": "Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hemophilia B" ], "interventions": [ { "name": "IB1001", "type": "BIOLOGICAL" }, { "name": "nonacog alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medexus Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 77, "start_date": "2009-01", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00768287" }, { "nct_id": "NCT00004993", "title": "Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoporosis" ], "interventions": [ { "name": "Parathyroid hormone (hPTH 1-34)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": "2001-08", "has_results": false, "last_update_posted_date": "2010-03-02", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004993" }, { "nct_id": "NCT01580293", "title": "A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "BAY94-9027", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "12 Years to 65 Years · Male only" }, "enrollment_count": 145, "start_date": "2012-04-23", "completion_date": "2019-11-21", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 14, "location_summary": "Tucson, Arizona • Sacramento, California • San Diego, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01580293" }, { "nct_id": "NCT00943293", "title": "Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Preleukemia", "Myeloproliferative Disorders", "Lymphoma", "Myeloma", "Graft Versus Host Disease" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Campath", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2003-05", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2014-03-17", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00943293" }, { "nct_id": "NCT02962804", "title": "Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2018-03-05", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02962804" }, { "nct_id": "NCT05050084", "title": "Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Buserelin", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Histrelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Relugolix", "type": "DRUG" }, { "name": "Triptorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2050, "start_date": "2021-12-06", "completion_date": "2031-11-11", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 567, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05050084" }, { "nct_id": "NCT00034047", "title": "Endometriosis : Traditional Medicine vs Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometriosis", "Pelvic Pain" ], "interventions": [ { "name": "Acupuncture", "type": "PROCEDURE" }, { "name": "Chinese Products", "type": "DRUG" }, { "name": "Nafarelin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Center for Complementary and Integrative Health (NCCIH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 50, "start_date": "2002-09", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2008-01-25", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 2, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00034047" }, { "nct_id": "NCT02272647", "title": "Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "IM Saline Placebo (0.25 ml)", "type": "DRUG" }, { "name": "IM Estradiol valerate (2.5 mg)", "type": "DRUG" }, { "name": "IM Saline Placebo (0.5 ml)", "type": "DRUG" }, { "name": "IM Estradiol valerate (5.0 mg)", "type": "DRUG" }, { "name": "Oral Micronized Progesterone", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" }, { "name": "Ghrelin (0.3 ug/kg)", "type": "DRUG" }, { "name": "Medroxyprogesterone - Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "50 Years to 80 Years · Female only" }, "enrollment_count": 47, "start_date": "2014-12", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2018-03-22", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02272647" }, { "nct_id": "NCT06483555", "title": "Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Metastatic Pancreatic Cancer", "Basal Cell Neoplasm" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "NALIRIFOX", "type": "DRUG" }, { "name": "Folfirinox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2025-02-06", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-27T08:53:09.310Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06483555" } ] }